Increasing unusual option volume: FSK AND PACB SGEN
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Morgan Stanley Calls Seagen (SGEN) A Catalyst Driven Idea for 'Pivotal Padcev Data in 1L Bladder Cancer'
June 21, 2022 4:22 PM EDTMorgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $173.00 price target on Seagen (NASDAQ: SGEN).
The analyst comments "Padcev (Enfortumab vedotin or EV) is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4 (a cell surface protein expressed on many... More
Seagen (SGEN) Seen Worth $200+ in a Takeover
June 21, 2022 12:53 PM EDTSeagen (NASDAQ: SGEN) is adding to Friday's gains as traders handicap the sale of the company following reports on Friday from the WSJ that Merck (NYSE: MRK) and others are eyeing a takeover of the biotech company.
Several analysts have weighed in on the potential deal and many view $200+ as the benchmark needed to get the deal done.
Oppenheimer analyst Jay Olson raised his price target on Seagen to $208 per share following the Merck speculation, which he thinks makes sense given recent dynamics, including:
1) SGEN and MRK... More
